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Abstract
Background: Activated microglial cells have been implicated in a number of neurodegenerative
disorders, including Alzheimer's disease (AD), multiple sclerosis (MS), and HIV dementia. It is well
known that inflammatory mediators such as nitric oxide (NO), cytokines, and chemokines play an
important role in microglial cell-associated neuron cell damage. Our previous studies have shown
that CD40 signaling is involved in pathological activation of microglial cells. Many data reveal that
cannabinoids mediate suppression of inflammation in vitro and  in vivo through stimulation of
cannabinoid receptor 2 (CB2).
Methods: In this study, we investigated the effects of a cannabinoid agonist on CD40 expression
and function by cultured microglial cells activated by IFN-γ using RT-PCR, Western
immunoblotting, flow cytometry, and anti-CB2  small interfering RNA (siRNA) analyses.
Furthermore, we examined if the stimulation of CB2 could modulate the capacity of microglial cells
to phagocytise Aβ1–42 peptide using a phagocytosis assay.
Results:  We found that the selective stimulation of cannabinoid receptor CB2 by JWH-015
suppressed IFN-γ-induced CD40 expression. In addition, this CB2 agonist markedly inhibited IFN-
γ-induced phosphorylation of JAK/STAT1. Further, this stimulation was also able to suppress
microglial TNF-α and nitric oxide production induced either by IFN-γ or Aβ peptide challenge in
the presence of CD40 ligation. Finally, we showed that CB2 activation by JWH-015 markedly
attenuated CD40-mediated inhibition of microglial phagocytosis of Aβ1–42 peptide. Taken together,
these results provide mechanistic insight into beneficial effects provided by cannabinoid receptor
CB2 modulation in neurodegenerative diseases, particularly AD.
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Background
Most neurodegenerative diseases are associated with
chronic inflammation resulting from the activation of
brain mononuclear phagocyte cells, called microglial
cells[1]. Because increased proliferation of microglial cells
is seen in brains of patients with multiple sclerosis (MS)
[2], Alzheimer's disease (AD)[3], and HIV [4]; and
because sustained microglial activation, associated with
these diseases, is known to have deleterious effects on the
surrounding neurons. [5], factors mediating microglial
activation are of intense interest.
Marijuana and its active constituent, {Delta}9-tetrahydro-
cannabinol (THC), suppress cell-mediated immune
responses (for review, see. [6]). Many of these effects are
mediated by the cannabinoid receptor 2 (CB2), as demon-
strated by the finding that THC inhibits helper T-cell acti-
vation by normal, but not CB2  knockout-derived,
macrophages [7]. While many studies have investigated
effects of cannabinoids on immune function, few studies
have examined their effects on the CD40 pathway [8].
The CD40 receptor is a 50 kDa type-I phosphoprotein
member of the tumor necrosis factor (TNF)-receptor
(TNFR) superfamily, which is expressed by a wide variety
of cells [8]. The ligand for CD40 (CD154, i.e. CD40L) is
mainly expressed by activated CD4+ T-cells. Following
ligation of CD40, numerous cell-type-dependent signal-
ing pathways are activated, leading to changes in gene
expression and function. These changes include several
signal transduction pathways: nuclear factor kappa-B (NF-
κB), mitogen-activated protein (MAP) kinases, TNFR-
associated factor proteins, phosphatidylinositol-3 kinase
(PI3K), and the Janus kinase (JAK)/signal transducer and
activator of transcription 1 (STAT1) pathway. [9,10]. Liga-
tion of CD40 on microglial cells leads to the production
of TNF-α and other unidentified neurotoxins [11-13].
Thus, signaling through CD40 on microglial cells induces
soluble mediators that could have important functional
roles in the central nervous system (CNS).
In the normal brain, microglial cells display a quiescent
phenotype, including low CD40 expression [14]. How-
ever, upon insult to the brain, microglial cells become
highly activated, altering their phagocytic and antigen-
presentation functions [15] as well as the production of
cytokines [13]. Mounting evidence implicates microglial
CD40 as contributing to the initiation and/or progression
of several neurodegenerative diseases [15]. In fact, block-
ing CD40-CD154 interactions by a neutralizing antibody
strategy prevents murine experimental autoimmune
encephalomyelitis (EAE) disease activity [16-19] as well as
AD-like pathology in mouse models of the disease [20].
Given the recently described immunomodulatory role of
cannabinoids, the importance of CD40-CD40L interac-
tion in neuroinflammatory diseases, and the clinical and
basic science studies suggesting that cannabinoids may be
therapeutic in AD and MS, [21-25], we examined, in the
present study, whether cannabinoids (primarily CB2 ago-
nist JWH-015) could oppose microglial CD40 expression
following interferon-γ (IFN-γ) challenge. Furthermore, we
examined whether CB2  agonist JWH-015 influences
microglial phagocytic function and/or proinflammatory
cytokine production after CD40 ligation.
Materials and methods
Peptides and drugs
Aβ1–42 peptide, purity greater than 95% according to man-
ufacturer's HPLC analysis, was obtained from QCB (Hop-
kinton, MA). Aβ1–42 peptide used for all experiments was
made fibrillar/aggregated, as previously described [26].
Briefly, 2 mg of Aβ1–42 was added to 0.9 ml of pure water
(Sigma), the mixture was vortexed, and 100 µl of 10 × PBS
(1 × PBS contains 0.15 M NaCl, 0.01 M sodium phos-
phate, pH 7.5) was added and the solution was incubated
at 37°C for 24 hr. The Cy3-Aβ peptide's conjugation was
carried out in strict accordance with the manufacturer's
described protocols. Briefly, Aβ1–42 was dissolved in 0.15
M sodium chloride and Cy3 mono-reactive NHS ester
(Amersham Biosciences, Piscataway, NJ) was diluted in
dimethyl sulfoxide (DMSO) to a working concentration
of 10 mg/mL and this was slowly added to the Aβ1–42 solu-
tion while stirring. The Cy3-Aβ1–42 solution was protected
from light while stirred for 45 min at room temperature.
To separate the free Cy3-dye, the solution was dialyzed
against 1 L of 0.15 M sodium chloride for 4 hr at room
temperature. The solution was then exchanged with fresh
0.15 M sodium chloride and dialyzed overnight at 4°C.
The next day the Cy3-Aβ1–42 solution was dialyzed against
1 L of 0.1 M PBS for 4 hr at room temperature, and again
dialyzed overnight using fresh 0.1 M PBS. The solution
was then syringe filter sterilized through a 0.22-µm filter
and the eluate was aliquoted and stored at -20°C until
used. Non-selective cannabinoid agonist (CP 55,940),
CB2 agonist (JWH-015), and THC were obtained from
Tocris (Ellisville, MO) and dissolved in 1% DMSO to a
stock concentration of 50 mM.
Animals and microglial cell cultures
Breeding pairs of BALB/c mice were purchased from Jack-
son Laboratory (Bar Harbor, ME) and housed in the ani-
mal facility at the University of South Florida, College of
Medicine. Murine primary culture microglial cells were
isolated from mouse cerebral cortices and grown in RPMI
1640 medium supplemented with 5% fetal calf serum
(FCS), 2 mM glutamine, 100 U/ml penicillin, 0.1 µg/ml
streptomycin, and 0.05 mM 2-mercaptoethanol according
to previously described methods [27]. Briefly, cerebralJournal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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cortices from newborn mice (1–2 day-old) were isolated
under sterile conditions and were kept at 4°C before
mechanical dissociation. Cells were plated in 75-cm2
flasks and complete medium was added. Primary cultures
were kept for 14 days so that only glial cells remained and
microglial cells were isolated by shaking flasks at 200 rpm
in a Lab-Line incubator-shaker. More than 98% of these
glial cells stained positive for microglial marker Mac-1
(CD11b/CD18; Boehringer Mannheim, Indianapolis, IN;
data not shown). All animal protocols were approved by
the Committee of Animal Research at the University of
South Florida, in accordance with the National Institutes
of Health guidelines. N9 microglial cells were cultured as
previously described [28].
Cannabinoids inhibit microglial CD40 expression induced by IFN-γ Figure 1
Cannabinoids inhibit microglial CD40 expression induced by IFN-γ. A, Mouse primary microglial cells were cultured 
in 6-well tissue-culture plates (5 × 105/well) and treated with THC (0.6 µM), CP55940 (5 µM) or selective cannabinoid CB2 
agonist (JWH015; 5 µM) in the presence or absence of IFN-γ (100 U/mL), or treated with vehicle (1% DMSO Control) or IFN-
γ alone (100 U/mL); B, In parallel 6-well tissue-culture plates, microglial cells were incubated with IFN-γ (100 U/mL) in the 
presence or absence of JWH-015 at the indicated doses. After 12 hr-treatments, these cells were prepared for FACS analysis 
of CD40 expression as described in Materials and methods. For A, ANOVA and post hoc testing showed significant differences 
of mean fluorescence (+/- SD with n = 3 for each condition) between IFN-γ treatment and IFN-γ treatment in the presence of 
THC, CP55940 or JWH-015 (p < 0.001). However, there was not a significant difference between IFN-γ/THC and either IFN-
γ/CP55940 or IFN-γ/JWH-015 (p > 0.05). For B, ANOVA and post hoc testing showed significant differences of mean fluores-
cence (+/- SD with n = 3 for each condition) between IFN-γ treatment and IFN-γ treatment in the presence of JWH-015 at 5 
µM, 2.5 µM and 1.25 µM (** p < 0.001). C, Western blot analysis by anti-mouse CD40 antibody shows CD40 protein expres-
sion and, by anti-β-actin antibody, shows β-actin protein (internal reference). D, Densitometric quantification of Western 
immunoblotting analysis from independent experiments (n = 2 for IFN-γ; n = 3 for IFN-γ/JWH-015 treatment) indicated that 
doses of JWH-015 of 1.25 µM or greater significantly (** p < 0.05) reduced IFN-γ-induced CD40 expression. CD40 expression 
is shown normalized to β-actin.Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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Reverse transcriptase (RT)-PCR analysis
Total RNA was isolated from primary cultured microglial
cells using Trizol reagent (Invitrogen, Carlsbad, CA) as
recommended in the manufacturer's protocol. RNA con-
centration was measured by spectrophotometry at 260
nm. RT-PCR was performed as described previously [28].
Briefly, cDNA was prepared by mixing 1 µg of total RNA
from each treatment with an oligo (dT) primer and the
MMLV reverse transcriptase (Invitrogen); the reaction mix
was incubated in a 37°C water-bath for 50 min before
heat inactivation of the mix by increasing the temperature
to 70°C for 10 min. This cDNA reaction mixture (20 µl)
was diluted with 180 µl of DNAase/RNAase-free water
and 10 µL of the cDNA solution was used for gene specific
PCR. The PCR primers used were CB2 sense: 5'-CCG GAA
AAG AGG ATG GCA ATG AAT-3' and antisense: 5'-CTG
CTG AGC GCC CTG GAG AAC-3' oligonucleotides were
designed to produce the partial 239 bp mouse CB2 cDNA
(MGI:104650); mouse β-actin sense: 5'-TTG AGA CCT
TCA ACA CCC-3' and β-actin antisense: 5'-GCA GCT CAT
AGC TCT TCT-3', which yields the 357 bp β-actin cDNA
fragment. Samples not undergoing reverse transcription
were run in parallel to control for technical errors leading
to DNA contamination (data not shown). Mouse β-actin
was amplified from all samples as a housekeeping gene to
normalize expression. A control (no template) was
included for each primer set. PCR was performed with
each cycle consisting of 94°C for 1 min, 55°C for 2 min,
and 72°C for 2 min, followed by a final extension step at
72°C for 10 min. PCR cycle numbers were kept low to
perform semi-quantitative PCR (actin, 25 cycles; CB2 30
cycles). PCR products were resolved on 1.2% ethidium
bromide-stained agarose gels, and visualized by ultravio-
let transillumination.
Flow cytometric analysis of microglial CD40 expression
Primary cultured microglial cells were plated in 6-well tis-
sue culture plates at 5 × 105 cells/well and incubated with
Cannabinoid receptor CB2 is expressed by cultured microglial cells Figure 2
Cannabinoid receptor CB2 is expressed by cultured microglial cells. A, RT-PCR analysis of murine primary cultured 
microglial cells. A 239-bp band corresponding to CB2 was specifically generated with primers described in the Materials and 
methods section. B, Graphical representation of RT-PCR band density ratio of CB2 expression normalized to β-actin (mean +/
- SD) is shown (n = 3 for each condition). ANOVA revealed significant between-group differences (control versus IFN-γ (50 U/
mL) and IFN-γ (50 U/mL) versus IFN-γ (100 U/mL); p < 0.005). C, Western immunoblot analysis of murine primary cultured 
microglial cells using specific antibodies targeting CB2 and β-actin proteins. D, Western blot band density is represented as 
ratio of CB2 to β-actin (mean +/- SD; n = 4 for each condition). ANOVA revealed significant between-group differences [Con-
trol versus IFN-γ (50 U/mL) and IFN-γ (50 U/mL) versus IFN-γ (100 U/mL); ** p < 0.005]. E, Cannabinoid receptor CB2 is 
expressed in microglial cells in situ. In white matter, microglial cells are positive in their somata and processes for CB2. White 
arrowheads show positive cells as indicated. The expression of CB2 (FITC; green) was co-localized with Iba-1, microglial cell 
marker (TRITC; red) as indicated. Bottom panel denotes merge signals. Bar denotes 10 µm.Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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THC, CP55940 or CB2 agonist (JWH-015) at different
doses in the presence or absence of IFN-γ (100 U/ml).
Twelve hours after incubation, these microglial cells were
washed with flow buffer [PBS containing 0.1% (w/v)
sodium azide and 2% (v/v) FCS] and re-suspended in 250
µl of ice-cold flow buffer for fluorescence activated cell
sorting (FACS) analysis, according to methods described
previously [28]. Briefly, cells were pre-incubated with
anti-mouse CD16/CD32 monoclonal antibody (clone
2.4G2, PharMingen, Los Angeles, CA) for 10 min at 4°C
to block non-specific binding to Fc receptors. Cells were
then spun down at 5,000 g washed 3 times with flow
buffer and then incubated with hamster anti-mouse
CD40-FITC or isotype control antibody-FITC (1:100 dilu-
tion; PharMingen) in flow buffer. After 30 min incubation
at room temperature, cells were washed twice with flow
buffer, re-suspended in 250 µL of flow buffer and ana-
lyzed by a FACScan™ instrument (Becton Dickinson, Fran-
klin Lanes, NJ). A minimum of 10,000 cells were accepted
for FACS analysis. Cells were gated based on morpholog-
ical characteristics such that apoptotic and necrotic cells
were not accepted for FACS analysis using CellQuest™
software (Beckton Dickinson). Percentages of positive
cells (i.e. CD40-expressing) were calculated as follows: for
each treatment, the mean fluorescence value for the iso-
type-matched control antibody was subtracted from the
mean fluorescence value for the CD40-specific antibody.
Western immunoblotting analysis
Murine microglial cell lysates (including primary cultured
microglial cells) were prepared in ice-cold lysis buffer (20
mM Tris, pH 7.5,150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM glycerolphosphate, 1 mM Na3VO4, 1 µg/ml leupep-
tin, and 1 mM PMSF) and protein concentration was
determined by the Bio-Rad protein assay as previously
described [29]. An aliquot corresponding to 100 µg of
total protein of each sample was separated by SDS-PAGE
and transferred electrophoretically to immunoblotting
PVDF membranes. Nonspecific antibody binding was
blocked with 5% nonfat dry milk for 1 hr at room temper-
ature in Tris-buffered saline (20 mM Tris and 500 mM
NaCl, pH 7.5). Subsequently, these membranes were first
hybridized with the goat anti-CB2 antibody (1:100 dilu-
tion; Santa Cruz) for 2 hr and then washed 3 times in TBS
and immunoblotting using an anti-goat HRP-conjugated
IgG secondary antibody as a tracer (Pierce Biotechnology,
Inc. Rockford, Illinois). Luminol reagent (Pierce Biotech-
nology, Inc.) was used to develop the blots. To demon-
strate equal loading, the same-membranes were then
stripped with β-mercaptoethanol stripping solution (62.5
mM Tris-HCl, pH 6.8,2% SDS, and 100 mM β-mercap-
toethanol), and finally re-probed with mouse mono-
clonal antibody to β-actin (Pierce Biotechnology, Inc.).
Immunochemistry analysis
Six mice (10 weeks of age, 3 male/3 female, C57 BL/6N;
Crea, Tokyo, Japan) were used to examine the expression
of CB2 in microglial cells. After mice were euthanized with
an overdose of sodium pentobarbital (50 mg/kg), the
brain was perfused transcardinally with 200 mL of 10 U/
mL heparin in saline followed by 200 mL of 4% parafor-
maldehyde in 0.1 M (pH 7.4) PBS. The brains were
removed and fixed in the same fixative overnight at 4°C,
dehydrated, and routinely embedded in paraffin with 16
hr processing. For in situ detection of CB2, sections (5 µm
in thickness) were deparaffinized and pretreated by
hydrolytic autoclaving in 10 mM citrate buffer (pH 6.0)
for 15 min at 121°C to retrieve antigens. Thereafter, sec-
tions were treated with endogenous peroxidase quench-
ing (0.3% H2O2 for 10 min) and pre-blocked with serum-
free blocking solution (DAKO, Carpinteria, CA) for 30
min prior to primary antibody incubation. Immunohisto-
chemistry was performed according to the manufacturer's
protocol using the Vectastain ABC Elite kit (Vector Labo-
ratories, Burlingame, CA) coupled with the diaminoben-
zidine reaction. For double labeling of CB2 and Iba-1
(microglial cell marker) in frozen sections, an additional
six mice were euthanized with the same anesthesia as
above, and then the brains were perfused transcardially
with 200 mL of 10 U/mL heparin in saline. Brains were
quick-frozen at -80°C for cryo-sectioning (5 µm in thick-
ness). Prior to immunohistochemistry, frozen sections
were fixed with 4% paraformaldehyde in 0.1 M (pH 7.4)
PBS for 1 hr, and pre-blocked with serum-free blocking
solution (DAKO, Carpinteria, CA) for 30 min. The follow-
ing primary and secondary antibodies were used: goat
anti-mouse CB2 antibody (1:400 dilution; Santa Cruz Bio-
technologies), rabbit anti-C-terminus of Iba-1 antibody
(1:500 dilution; Wako Pure chemical Industries, Osaka,
Japan), FITC-conjugated donkey anti-goat IgG (1:50 dilu-
tion; Jackson ImmunoResearch Laboratories, West Grove,
PA), and TRITC-conjugated swine anti-rabbit IgG (1:50
dilution; DAKO, Carpinteria, CA). In addition, for a neu-
tralization test (pre-absorption test), Goat anti-mouse
CB2 antibody was pre-incubated for 30 min with a five-
fold (w/v) excess of mouse CB2 blocking peptides (Santa
Cruz Biotechnologies). Whereas the appropriate isotype
control serum or PBS was used instead of primary anti-
body or ABC reagent as a negative control, spleen was
used as a positive control. Counterstaining was performed
with hematoxylin.
CB2 small interfering RNA
N9 cells were transfected with specific murine CB2 target-
ing siRNA designed to knockdown murine CB2 expression
(Humesis Biotechnology Corporation, New Orleans, LA).
Briefly, N9 cells were seeded in 24-well plates and cul-
tured until they reached 70% confluency. The cells were
then transfected with 100 nM anti-CB2 siRNA or anti-Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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green fluorescent protein (GFP; non-targeting control;
Humesis) using Code-Breaker transfection reagent
(Promega, Madison, WI) and cultured for an additional
18 hr in serum-free MEM. The cells were allowed to
recover for 24 hr in complete medium (MEM 10% FBS)
before treatments. The cells were evaluated by Western
immunodetection for the expression of CB2 using anti-
CB2 antibodies (Santa Cruz) following siRNA treatment.
The cells were also cultured for 4 hr with LPS, JWH-015,
or various combinations, and TNF-α release was meas-
ured by specific enzyme-linked immunosorbent assay
(ELISA). Transfection efficiency was determined to be
greater than 80% (data not shown) using no-RISC
siGLOW obtained from Dharmacon (Lafayette, CO).
TNF-α and NO (nitric oxide) analyses
Murine primary cultured microglial cells were plated in
24-well tissue-culture plates (Costar, Cambridge, MA) at 1
× 105 cells per well and stimulated for 24 hr with either
IFN-γ (100 U/ml)/CD40L protein (2.5 µg/ml) or Aβ1–42 (3
µM)/CD40L protein (2 µg/ml) in the presence or absence
of CB2 agonist JWH-015 (5 µM). Cell-free supernatants
were collected and stored at -70°C until analysis. TNF-α
and NO levels in the supernatants were examined using
ELISA kits (R&D Systems) and NO assay (Calbiochem) in
strict accordance with the manufacturers' protocols. Cell
lysates were also prepared and the Bio-Rad protein assay
(Hercules, CA) was performed to measure total cellular
protein. Results are shown as mean pg of TNF-α or NO per
mg of total cellular protein (+/- SD).
JAK/STAT1 signaling pathway analysis
Primary culture microglial cells were plated in 6-well tis-
sue culture plates at a density of 5 × 105 cells per well and
co-incubated with IFN-γ (100 U/mL) in the presence or
absence of a dose range of CB2 agonist (0.31, 0.62, 1.25,
Cultured microglial cells (N9) treated with LPS and 100 nM anti-murine CB2 siRNA lose their ability to respond to CB2 agonist,  JWH-015 Figure 3
Cultured microglial cells (N9) treated with LPS and 100 nM anti-murine CB2 siRNA lose their ability to 
respond to CB2 agonist, JWH-015. A, Microglial cells treated with LPS (100 ng/mL) secreted large quantities of TNF-α (n = 
3, **p < 0.005). Co-treatment with JWH-015 (5 µM) attenuated LPS-induced TNF-α release. Pre-treatment with anti-CB2 
siRNA abolished JWH-015's ability to reduce LPS-induced TNF-α release (n = 3, ** p < 0.05). Non-targeting anti-GFP siRNA 
control had no effect. B and C, Western blot using an anti-murine CB2 antibody demonstrates that 100 nM anti-CB2 siRNA sig-
nificantly reduced expression of CB2 protein by N9 microglial cells after 48 hr (n = 2, ** p < 0.05).Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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2.5 and 5.0 µM) for 30 min. At the end of the treatment
period, microglial cells were washed in ice-cold PBS three
times and lysed in ice-cold lysis buffer. After incubation
for 30 min on ice, samples were centrifuged at high speed
for 15 min, and supernatants were collected. Total protein
content was estimated using the Bio-Rad protein assay.
For phosphorylation of JAK1 and JAK2, membranes were
first hybridized with phospho-specific Tyr1022/1023
JAK1 or Tyr1007/1008 JAK2 antibody (Cell Signaling
Technology, Beverly, MA) and then stripped and finally
analyzed by total JAK1 or JAK2 antibody. For STAT1 phos-
phorylation, membranes were probed with a phospho-
Ser727 STAT1 antibody (Cell Signaling Technology) and
stripped with stripping solution and then re-probed with
an antibody that recognizes total STAT1 (Cell Signaling
Technology). Alternatively, membranes with identical
samples were probed either with phospho-JAK or STAT1,
or with an antibody that recognizes total JAK or STAT1.
Immunoblotting was performed with a primary antibody
followed by an anti-rabbit HRP-conjugated IgG secondary
antibody as a tracer. After washing in TBS the membranes
were incubated in luminol reagent and exposed to x-ray
film.
Microglial Aβ phagocytosis assays
Microglial phagocytosis of fibrillar/aggregated Aβ1–42 pep-
tide was carried out in a manner similar to previously
described protocols [30-32]. Microglial cells were cultured
at 5 × 105/well in 6-well tissue-culture plates with glass
inserts (for fluorescence microscopy). The following day,
microglial cells were treated with Cy3-conjugated Aβ1–42
(3 µM) and CD40L protein (2.5 µg/mL) in the presence or
Cannabinoid CB2 agonist treatment opposes IFN-γ-induced phosphorylation of JAK/STAT1 in microglial cells Figure 4
Cannabinoid CB2 agonist treatment opposes IFN-γ-induced phosphorylation of JAK/STAT1 in microglial cells. 
A, B, Primary microglial cells were seeded in 6-well tissue-culture plates (5 × 105/well) and treated with IFN-γ (100 U/mL) in 
the presence or absence of CB2 agonist (JWH-015) at the indicated doses for 30 min. Cell lysates were prepared from these 
cells and subjected to Western immunoblotting using antibodies against phospho-JAK1 (Tyr1022/1023) and JAK2 (Tyr1007/
1008), or total JAK1 and JAK2, as indicated. Densitometric quantification of all Western immunoblots results are summarized 
by the histograms below, representative of Western immunoblots from two independent experiments. Dose-dependent 
reductions in phospho-JAK1/total JAK1 and phosphor-JAK2/total JAK2 correlated with JWH-015 treatments, becoming signifi-
cant (** p < 0.05) at doses greater than or equal to 1.25 µM and 0.62 µM for JAK1 and JAK2, respectively. C, In parallel exper-
iments, cell lysates were subjected to Western immunoblotting using anti-phospho-STAT1 (Ser727) or anti-total STAT1 
antibody as indicated. Dose-dependent reductions in phospho-Stat1/total Stat1 correlated with JWH-015 treatments, becom-
ing significant (** p < 0.05) at doses greater than or equal to 0.62 µM.Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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absence of CB2 agonist (5 µM) for 3 hr. In parallel dishes,
microglial cells were incubated with Cy3-conjugated Aβ1–
42 under the same treatment conditions above except they
were incubated at 4°C to control for non-specifically cel-
lular association of Cy3-Aβ1–42. Microglial cells were then
rinsed 3 times in Aβ1–42-free complete medium and the
medium was exchanged with fresh Aβ1–42-free complete
medium for 10 min both to allow for removal of non-
incorporated Cy3-Aβ1–42 and to promote concentration of
the Cy3-Aβ1–42 peptide into phagosomes. This medium
was withdrawn and microglial cells were rinsed 3 times
with ice-cold PBS. For fluorescence microscopy, micro-
glial cells on glass coverslips were fixed for 10 min at 4°C
with 4% (w/v) paraformaldehyde (PFA) diluted in PBS.
After three successive rinses in TBS, microglial cell nuclei
were detected by incubation with DAPI for 10 min and
finally mounted with fluorescence mounting media con-
taining Slow Fade antifading reagent (Molecular Probes,
Eugene, OR) and then viewed under an Olympus IX71/
IX51 fluorescence microscope equipped with a digital
camera system to allow for digital capture of images
(40×).
For immunoblot detection of cell-associated Aβ, primary
microglial cells were plated in 6-well tissue culture plates
with glass inserts at 5 × 105 cells/well and treated as
described for immunofluorescense detection of Cy3-Aβ1–
42 except that these experiments employed Aβ1–42. Immu-
noblotting was carried out with the monoclonal anti-
human Aβ antibody (BAM-10, 1:1,000 dilution; Sigma)
followed by an anti-mouse IgG-HRP as a tracer. Blots were
developed using the Immun-Star chemiluminescence
substrate. The membranes were stripped and then re-
probed with a reference anti-mouse β-actin monoclonal
antibody, which allows for quantification of the band
density ratio of Aβ to β-actin by densitometric analysis.
Statistical analysis
Data are presented as mean +/- SD. All statistics were ana-
lyzed using a one-way multiple-range analysis of variance
CB2 stimulation attenuates microglial proinflammatory cytokine release Figure 5
CB2 stimulation attenuates microglial proinflammatory cytokine release. Mouse primary microglial cells were 
seeded in 24-well tissue-culture plates (1 × 105/well) and co-treated with either IFN-γ (100 U/mL)/CD40L protein (2 µg/mL) or 
Aβ1–42 (1 µM)/CD40L protein (2 µg/mL) in the presence or absence of cannabinoid receptor CB2 agonist (JWH015, 5 µM) for 
24 hr. Cell cultured supernatants were collected and subjected to TNF-α cytokine ELISA (A) and NO release assay (B) as indi-
cated. TNF-α production was represented as mean pg of TNF-α per mg of total cellular protein (+/- SD). Similar results were 
obtained in three independent experiments. ANOVA and post hoc testing revealed significant differences between IFN-γ/
CD40L and IFN-γ/CD40L and JWH-015 (** p < 0.005); Aβ1–42/CD40L and Aβ1–42/CD40L plus JWH-015 treatment (** p < 
0.001).Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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test (ANOVA) for multiple comparisons. A value of p <
0.05 was considered significant.
Results
Stimulation of CB2 inhibits IFN-γ-induced CD40 expression 
in microglial cells
In previous studies, we and others showed that expression
of constitutive levels of CD40 on microglial cells can be
induced in response to IFN-γ challenge [28,33]. We
recently reported that lovastatin treatment inhibits CD40
expression in cultured microglial cells [34]. To investigate
cannabinoid regulation of CD40 expression in microglial
cells, primary cultured murine microglial cells were
treated with IFN-γ (100 U/ml) in the presence or absence
of THC, CP55940 or JWH-015 for 12 hr and the expres-
sion of CD40 was analyzed by flow cytometry. As
expected, the treatment of cultured microglial cells with
THC, CP55940 and JWH-015 significantly inhibited
CD40 expression induced by IFN-γ (Figure 1A). Treatment
with the CB2 agonist, JWH-015, inhibited IFN-γ-induced
CD40 expression in a dose-related manner (Figure. 1B).
Furthermore, Western blotting examination consistently
showed that JWH-015 co-treatment mitigates the induci-
ble increase in CD40 protein expression in primary cul-
tured microglial cells after IFN-γ treatment (Figure. 1C,
D). Taken together, these findings suggest that stimula-
tion of CB2 decreases CD40 expression on primary cul-
tured microglial cells.
Microglial cells express CB2
In order examine whether CB2 might be expressed in cul-
tured microglial cells, we first isolated total RNA from pri-
mary cultured microglial cells for reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis. Results
show that CB2 mRNA is constitutively expressed in pri-
mary cultured microglial cells (Figure. 2A) and, more
importantly, is significantly increased following IFN-γ(50
U/ml and 100 U/ml) challenge (Figure. 2A, B). Further-
more, Figure 2C and 2D, show that CB2 protein is detected
in primary cultured microglial cells, and is also markedly
increased following the challenge with IFN-γ, by Western
blotting. To further evaluate CB2 expression in microglial
cells, we performed immunohistochemistry on adult
mouse brain, and found that adult mouse microglial cells
stained positively for CB2 (Figure. 2E, top). To rule out the
possibility that microglial cells non-specifically bound
anti-CB2 antibody, we pre-absorbed the goat anti-mouse
CB2 antibody with mouse CB2 blocking peptide. The CB2
signal is markedly reduced in mouse brain when the
blocking peptide is employed (data not shown). Moreo-
ver, immunohistochemical analysis indicated that expres-
sion of CB2 by microglial cells was co-localized with
microglial cell marker Iba-1 (Figure. 2E, bottom).
Anti-CB2 small interfering RNA blocked effect of CB2 
agonist JWH-015 treatment
N9 cells, transfected for 18 hr with specific murine CB2
targeting siRNA (100 nM), were treated for 4 hr with LPS,
JWH-015, or in various combinations, and TNF-α release
was measured by ELISA (Figure 3A). Anti-CB2 siRNA was
able to completely abolish JWH-015-mediated reductions
in LPS-induced TNF-α release. In addition, to evaluate the
knock-down efficiency, we performed Western blot using
anti-CB2 antibody and found a significantly decreased
level of CB2 expression in siRNA transfected condition
(Figure 3B). These data indicate that JWH-015 is activat-
ing CB2 to oppose the TNF-α release caused by LPS treat-
ment.
CB2 agonist inhibited JAK/STAT signaling induced by IFN-γ 
in microglial cells
Previous reports demonstrate the ability of IFN-γ to
potently induce microglial CD40 expression [28]. The sig-
nal transduction pathway involved in this induction most
likely involves elements of the JAK/STAT signaling path-
way [35,36]. Interestingly, many of the factors (cytokines,
neurotrophins, neuropeptides, statins) that inhibit IFN-γ-
induced microglial CD40 expression do so by modifica-
tion of the JAK/STAT pathway [34-39]. Therefore, we
examined the effects of stimulation of CB2 on the JAK/
STAT signaling pathway in primary cultured microglial
cells. Cultured microglial cells were treated with IFN-γ for
30 min in the presence or absence of a dose range of CB2
agonist JWH-015. Western immunoblotting analysis
revealed that JWH-015 treatment markedly mitigated
JAK1 Tyr1022/1023 and JAK2 Tyr1007/1008 phosphor-
ylation in dose-dependent manner (Figure. 4A, B). Fur-
ther, it is well known that during IFN-γ interaction with its
heterodimer type II cytokine receptor, the JAKs are directly
activated leading to STAT1 phosphorylation [35,36,38].
Accordingly, we examined the effects of CB2 stimulation
on STAT1 phosphorylation, in the same dose range men-
tioned above, on primary microglial cells treated with
IFN-γ for 30 min. Results showed that JWH-015 co-treat-
ment significantly inhibited Ser727 phosphorylation of
the STAT1 protein at 10 µM (Figure. 3C). Unstimulated
microglial cells displayed very little detectable JAK1,2 or
STAT-1 phosphorylation (data not shown).
Stimulation of CB2 inhibits functional CD40 signaling in 
microglial cells
To examine the functional consequences of CB2 agonist
treatment on CD40 expression, we stimulated mouse pri-
mary microglial cells with either IFN-γ/CD40L protein
[28,40,41] or Aβ1–42/CD40L protein in the presence or
absence of JWH-015 for 24 hr. Supernatants from each
treatment condition were examined by ELISA for pro-
inflammatory molecules that we have previously
described as being induced by microglial CD40 ligationJournal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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[14,27-31]. As we expected, ELISA measurements revealed
that either IFN-γ /CD40L or Aβ1–42/CD40L increased the
secretion of the pro-inflammatory molecules TNF-α and
NO, as indicated in Figure 5A and 5B. However, when CB2
is stimulated by the presence of JWH-015, these pro-
inflammatory molecules were significantly reduced. The
canonical microglial function in the CNS is thought to be
phagocytosis, and given that IFN-γ and CD40 signaling
are maturation agents that oppose this phagocytic func-
tion [15,42-47], we examined whether CB2 agonist co-
treatment could rescue microglial phagocytic function.
Murine primary microglial cultures were exposed to 3 µM
CB2 stimulation modulates microglial phagocytic function Figure 6
CB2 stimulation modulates microglial phagocytic function. A, Mouse primary microglial cells were seeded in 6-well tis-
sue culture plates with glass inserts (5 × 105cells/well) and treated with 3 µM Cy3™-Aβ1–42 in the absence (a and b; Control) 
or presence of either CD40L protein (c and d 2.5 µg/mL) or JWH-015 (e and f; 5 µM), or both JWH-015 and CD40L protein 
(g and h). After 3 hr these cells were washed and fixed (see Materials and Methods). Subsequently, immunofluorescence micro-
scopy examination was performed using a 40 X objective with appropriate filter selection. The darkfield images a, c, e, and g 
show the fluorescence of Cy3™ labeled Aβ1–42 whereas, b, d, f, and h show only the DAPI nuclear stain of the same fields. B, In 
parallel experiments, under the same treatment conditions, microglial cell lysates were prepared for Western immunoblotting 
analysis (see Materials and methods) of cell-associated Aβ1–42 using anti-Aβ antibody (BAM-10, Sigma). C, Aβ mean band densi-
ties are graphically represented as ratios to β-actin +/- SD (n = 3 for each condition). ANOVA revealed significant between-
group differences (JWH-015/Aβ versus CD40L/Aβ and Aβ/CD40L versus JWH-015/CD40L/Aβ; ** p < 0.005), and post hoc test-
ing showed significant differences between CD40L/Aβ and JWH-015/CD40L/Aβ (** p < 0.005).Journal of Neuroinflammation 2005, 2:29 http://www.jneuroinflammation.com/content/2/1/29
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of Aβ1–42  (for immunoblotting) or Cy3™-Aβ1–42  (for
phagocytosis assay) in the presence or absence of CD40L
protein or CD40L protein/JWH-015. After 3 hr, the
amount of phagocytosed Aβ1–42 peptide was determined
by both qualitative immunofluorescence studies (Figure
6A) and with quantitative immunoblotting experiments
(Figure 6B and 6C). As shown in Figure 6A, CD40 ligation
decreased microglial phagocytic function compared to
controls (Figure 6A, panel a, b versus c, d), while CB2 ago-
nist treatment alone increased compared to control (Fig-
ure 6A, panel a, b versus c, d). Interestingly, the presence
of JWH-015 rescued microglial phagocytosis of Cy3-Aβ1–
42 following CD40L treatment (Figure. 6A, panel g, h ver-
sus e, f). In a parallel experiment, we further showed that
CB2  stimulation by JWH-015 resulted in a significant
attenuation of CD40L-mediated impairment of microglial
phagocytosis of Aβ1–42, as evidenced by increased band
density ratio of Aβ to β-actin using Western immunoblot-
ting (Figure. 6B and 6C).
Discussion
The findings of the present study suggest that cannabi-
noids, namely CB2  agonist JWH-015, reduce IFN-γ-
induced up-regulation of CD40 expression in mouse
microglial cells by interfering with the JAK/STAT1 path-
way. Given that this finding is consistent with the immu-
nosuppressive effects of cannabinoids reported previously
[48], the significance of our present findings must be con-
sidered in the context of the function of microglial CD40.
Aberrant expression of CD40 by microglial cells, in con-
junction with the release of TNF-α, is directly correlated
with pathogenic events occurring in the CNS of MS
patients [49-51] and in the EAE mouse model of MS [52].
In AD, activated microglial cells are considered a major
contributor to the local inflammatory responses evi-
denced in neuritic plaques. Furthermore, the CD40-
CD40L dyad is potentiated, as can be seen from the
increased numbers of CD40-positive microglial cells as
well as increased CD40L expression on astrocytes in AD
[53,54]. Our previous work has shown a correlation
between increased levels of Aβ peptide and enhanced
CD40 expression on microglial cells derived from the
Tg2576 mouse model of AD [28]. We also reported that
Aβ peptide can synergize with the IFN-γ signaling pathway
to induce microglial CD40 expression and subsequent
neurotoxicity [28].
A review of the molecular basis of CD40 expression in
macrophages/microglial cells illuminates the critical role
of the JAK/STAT1 pathway [55]. In this study, we show
that the CB2  agonist JWH015 inhibits IFN-γ-induced
microglial CD40 expression by opposing JAK/STAT1
pathway activation. One possible mechanism of
JWH015's inhibition of the JAK/STAT1 pathway is pro-
vided by a recent report showing that treatment with
novel cannabinoid, PRS-211,092, significantly decreased
Concanavalin A-induced liver injury in mice that was
accompanied by an induction of early gene expression of
the suppressors of cytokine signaling (SOCS-1 and 3). The
SOCS proteins act as negative regulators of the JAK/STAT1
pathway either by binding and inhibiting JAK tyrosine
kinases or by inhibiting binding of STAT1 factors to the
cytoplasmic domains of the receptors [56].
We previously reported that mechanisms that antagonize
microglial CD40 expression or CD40 signaling could also
block microglial production of proinflammatory media-
tors [27]. In this study, we have also shown that CB2 ago-
nist JWH-015 similarly inhibits microglial CD40 ligation-
induced production of proinflammatory cytokines. This
finding is consistent with studies showing that CB2 ago-
nists inhibit microglial production of proinflammatory
mediators [22]. These data, suggesting that the CB2 ago-
nist JWH-015 promotes microglial phagocytic function,
are of great interest given that mechanisms driving the
clearance of cerebral Aβ underlie principles of many ther-
apeutic strategies for AD.
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